Azithromycin in COVID-19 patients: pharmacological mechanism, clinical evidence and prescribing guidelines

J Sultana, PM Cutroneo, S Crisafulli, G Puglisi… - Drug safety, 2020 - Springer
The global COVID-19 pandemic has led to a race to find medications that can improve the
prognosis of the disease. Azithromycin, in association with hydroxychloroquine or …

Association of cardiovascular disease with coronavirus disease 2019 (COVID-19) severity: a meta-analysis

G Aggarwal, I Cheruiyot, S Aggarwal, J Wong… - Current problems in …, 2020 - Elsevier
Observational studies have reported an association between underlying cardiovascular
diseases (CVD) and worse prognosis in COVID-19 patients, but this still remains unclear …

Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial

W Tang, Z Cao, M Han, Z Wang, J Chen, W Sun, Y Wu… - bmj, 2020 - bmj.com
Objective To assess the efficacy and safety of hydroxychloroquine plus standard of care
compared with standard of care alone in adults with coronavirus disease 2019 (covid-19) …

BTS guidelines for the management of community acquired pneumonia in adults: update 2009

WS Lim, SV Baudouin, RC George, AT Hill… - Thorax, 2009 - thorax.bmj.com
SYNOPSIS OF RECOMMENDATIONS A summary of the initial management of patients
admitted to hospital with suspected community acquired pneumonia (CAP) is presented in …

Azithromycin and the risk of cardiovascular death

WA Ray, KT Murray, K Hall, PG Arbogast… - New England Journal …, 2012 - Mass Medical Soc
Background Although several macrolide antibiotics are proarrhythmic and associated with
an increased risk of sudden cardiac death, azithromycin is thought to have minimal …

COVID-19: therapeutics and their toxicities

MA Chary, AF Barbuto, S Izadmehr, BD Hayes… - Journal of Medical …, 2020 - Springer
SARS-CoV-2 is a novel coronavirus that emerged in 2019 and is causing the COVID-19
pandemic. There is no current standard of care. Clinicians need to be mindful of the toxicity …

Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases

P Zarogoulidis, N Papanas, I Kioumis… - European journal of …, 2012 - Springer
Background Macrolides have long been recognised to exert immunomodulary and anti-
inflammatory actions. They are able to suppress the “cytokine storm” of inflammation and to …

Use of azithromycin and death from cardiovascular causes

H Svanström, B Pasternak, A Hviid - New England Journal of …, 2013 - Mass Medical Soc
Background Azithromycin use is associated with an increased risk of death from
cardiovascular causes among patients at high baseline risk. Whether azithromycin confers a …

Cardiotoxicity of antimalarial drugs

NJ White - The Lancet infectious diseases, 2007 - thelancet.com
There are consistent differences in cardiovascular state between acute illness in malaria
and recovery that prolong the electrocardiographic QT interval and have been …

Triazole antifungal agents in invasive fungal infections: a comparative review

C Lass-Flörl - Drugs, 2011 - Springer
Invasive fungal disease continues to be a problem associated with significant morbidity and
high mortality in immunocompromised and, to a lesser extent, immunocompetent …